IBJNews

Lilly, Roche drugs chosen for Alzheimer’s prevention trial

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.

The experimental medicines will be tested in a trial called DIAN TU involving 160 people with a mutation that guarantees they will develop Alzheimer’s at an early age, perhaps as young as 30, the university said in a statement Wednesday.

If the trial is successful, it may lead to those drugs being widely used for people who may have a family history of the disease. Solanezumab slowed the decline in some patients with mild Alzheimer’s and provided no benefit to more advanced patients, Indianapolis-based Lilly announced in August. On Oct. 8, an independent group of scientists confirmed the findings.

“Trying to prevent Alzheimer’s symptoms from ever occurring is a new strategy,” said John C. Morris, the trial’s principal investigator, in Wednesday’s statement. That will be the goal of the research, he said.

Lilly and Roche, based in Basel, Switzerland, have agreed to make their treatments available for the study at no cost, and will support the trial with grants. Another $4.2 million has been given to the investigation from the Alzheimer’s Association, an advocacy group based in Chicago.

The trial will be conducted by Washington University’s unit of the Dominantly Inherited Alzheimer’s Network, or DIAN, an international group of scientists studying rare genetic mutations that cause the disease. The information gathered in these patients may enable better treatment for all dementia patients.

Roche’s gantenerumab binds to clumps of beta amyloid, a protein thought to cause the disease. The drug is thought to help remove the clumps from the brain, and is in a mid- to late-stage company trial that started in 2010. Lilly's solanezumab removes the beta amyloid before it forms plaques.

Another Lilly drug, called a beta secretase inhibitor, is in testing by the company and may be included in the university research as well, according to Wednesday’s statement. That drug is thought to work by reducing the amount of beta amyloid produced in the brain.

The trial, which may start early next year, will test the medicines in inherited early-onset Alzheimer’s patients. The researchers will see if the treatments can prevent the loss of brain function.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. How can any company that has the cash and other assets be allowed to simply foreclose and not pay the debt? Simon, pay the debt and sell the property yourself. Don't just stiff the bank with the loan and require them to find a buyer.

  2. If you only knew....

  3. The proposal is structured in such a way that a private company (who has competitors in the marketplace) has struck a deal to get "financing" through utility ratepayers via IPL. Competitors to BlueIndy are at disadvantage now. The story isn't "how green can we be" but how creative "financing" through captive ratepayers benefits a company whose proposal should sink or float in the competitive marketplace without customer funding. If it was a great idea there would be financing available. IBJ needs to be doing a story on the utility ratemaking piece of this (which is pretty complicated) but instead it suggests that folks are whining about paying for being green.

  4. The facts contained in your post make your position so much more credible than those based on sheer emotion. Thanks for enlightening us.

  5. Please consider a couple of economic realities: First, retail is more consolidated now than it was when malls like this were built. There used to be many department stores. Now, in essence, there is one--Macy's. Right off, you've eliminated the need for multiple anchor stores in malls. And in-line retailers have consolidated or folded or have stopped building new stores because so much of their business is now online. The Limited, for example, Next, malls are closing all over the country, even some of the former gems are now derelict.Times change. And finally, as the income level of any particular area declines, so do the retail offerings. Sad, but true.

ADVERTISEMENT